Literature DB >> 21179270

The role of photodynamic therapy for hilar cholangiocarcinoma.

Young Koog Cheon1.   

Abstract

The prognosis for hilar cholangiocarcinoma is limited by tumor spread along the biliary tree leading to refractory obstructive cholestasis, cholangitis, and liver failure. Palliation with biliary endoprostheses results in median survival times of 4-6 months for advanced bile duct cancer. Photodynamic therapy (PDT) is a local photochemical tumor treatment consisting of a photosensitizing agent combined with laser irradiation of a distinct wavelength. Tumor ablation with PDT combined with biliary stenting reduces cholestasis and significantly improves median survival time. However, the treatment is not widely available, and the photosensitizers used for PDT cause prolonged photosensitivity. Optimum control of tumor spread along the bile ducts and control of cholestasis and cholangitis will prolong survival in one to two thirds of patients, and renders them suitable for other antitumor therapies.

Entities:  

Keywords:  Bile duct neoplasms; Cholangiocarcinoma; Photodynamic therapy; Photosensitizing agents

Mesh:

Year:  2010        PMID: 21179270      PMCID: PMC2997961          DOI: 10.3904/kjim.2010.25.4.345

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  33 in total

1.  Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma.

Authors:  W R Jarnagin; Y Fong; R P DeMatteo; M Gonen; E C Burke; J Bodniewicz BS; M Youssef BA; D Klimstra; L H Blumgart
Journal:  Ann Surg       Date:  2001-10       Impact factor: 12.969

2.  Endoscopic application of photodynamic therapy for cholangiocarcinoma.

Authors:  A Rumalla; T H Baron; K K Wang; G J Gores; L M Stadheim; P C de Groen
Journal:  Gastrointest Endosc       Date:  2001-04       Impact factor: 9.427

3.  Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival.

Authors:  F Berr; M Wiedmann; A Tannapfel; U Halm; K R Kohlhaw; F Schmidt; C Wittekind; J Hauss; J Mössner
Journal:  Hepatology       Date:  2000-02       Impact factor: 17.425

Review 4.  Current status of photodynamic therapy of Barrett's esophagus.

Authors:  K K Wang
Journal:  Gastrointest Endosc       Date:  1999-03       Impact factor: 9.427

5.  Prospective study of the effectiveness of percutaneous transhepatic photodynamic therapy for advanced bile duct cancer and the role of intraductal ultrasonography in response assessment.

Authors:  C S Shim; Y K Cheon; S W Cha; S Bhandari; J H Moon; Y D Cho; Y S Kim; L S Lee; M S Lee; B S Kim
Journal:  Endoscopy       Date:  2005-05       Impact factor: 10.093

Review 6.  An update on photodynamic therapy applications.

Authors:  Thomas J Dougherty
Journal:  J Clin Laser Med Surg       Date:  2002-02

7.  Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy.

Authors:  Thomas Zoepf; Ralf Jakobs; Joachim C Arnold; Darius Apel; Jürgen F Riemann
Journal:  Am J Gastroenterol       Date:  2005-11       Impact factor: 10.864

8.  Distribution and pharmacokinetics of Photofrin in human bile duct cancer.

Authors:  S A Pahernik; M Dellian; F Berr; A Tannapfel; C Wittekind; A E Goetz
Journal:  J Photochem Photobiol B       Date:  1998-11       Impact factor: 6.252

9.  Adjuvant photodynamic therapy for bile duct carcinoma after surgery: a preliminary study.

Authors:  Atsushi Nanashima; Hiroyuki Yamaguchi; Shinichi Shibasaki; Noboru Ide; Terumitsu Sawai; Takashi Tsuji; Shigekazu Hidaka; Yorihisa Sumida; Tohru Nakagoe; Takeshi Nagayasu
Journal:  J Gastroenterol       Date:  2004-11       Impact factor: 7.527

10.  Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy.

Authors:  Young Koog Cheon; Young Deok Cho; Jong Ho Moon; Jae Young Jang; Young Seok Kim; Yun Soo Kim; Moon Sung Lee; Joon Seong Lee; Chan Sup Shim
Journal:  Am J Gastroenterol       Date:  2007-07-07       Impact factor: 10.864

View more
  4 in total

1.  Photodynamic therapy in unresectable cholangiocarcinoma: not for the uncommitted.

Authors:  Jayant P Talreja; Marisa Degaetani; Kristi Ellen; Timothy Schmitt; Monica Gaidhane; Michel Kahaleh
Journal:  Clin Endosc       Date:  2013-07-31

2.  Photodynamic therapy prolongs metal stent patency in patients with unresectable hilar cholangiocarcinoma.

Authors:  Tae Yoon Lee; Young Koog Cheon; Chan Sup Shim; Young Deok Cho
Journal:  World J Gastroenterol       Date:  2012-10-21       Impact factor: 5.742

3.  Reversal of jaundice in two patients with inoperable cholangiocarcinoma treated with Cisplatin and gemcitabine combination.

Authors:  Maarten Criel; Filip Geurs; Siegfried Ponette; Katrien Bulte; Johan Ponette
Journal:  Case Reports Hepatol       Date:  2012-03-20

4.  Long-term outcome of photodynamic therapy with systemic chemotherapy compared to photodynamic therapy alone in patients with advanced hilar cholangiocarcinoma.

Authors:  Mi Jin Hong; Young Koog Cheon; Eung Jun Lee; Tae Yoon Lee; Chan Sup Shim
Journal:  Gut Liver       Date:  2014-05       Impact factor: 4.519

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.